Data Demonstrating Financial Impact Of INPEFA To Be Presented At The Academy Of Managed Care Pharmacy Nexus 2023 National Meeting
Portfolio Pulse from Benzinga Newsdesk
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) announced that findings from two studies on the cost-effectiveness and budget impact of INPEFA, a drug recently approved by the FDA for heart failure treatment, will be presented at the Academy of Managed Care Pharmacy Nexus 2023 National Meeting. The company believes that the cost-effectiveness analysis and budget impact model for INPEFA will be crucial in driving decisions for formulary inclusion of this innovation.
October 11, 2023 | 1:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Lexicon Pharmaceuticals' INPEFA drug's cost-effectiveness and budget impact studies could influence its formulary inclusion, potentially increasing its market reach and revenues.
The presentation of cost-effectiveness and budget impact studies of INPEFA at a major pharmacy meeting could influence its inclusion in formularies, which are lists of medications approved for prescription within a particular healthcare system. If included, this could increase the drug's market reach and potentially boost Lexicon's revenues.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100